B2: Pulmonary hypertension in lung cancer (Prof. Grimminger, Prof. Gattenlöhner)
In subproject B2, a large cohort of lung tumour patients is being examined for PH in order to determine its frequency and influence on tumour therapy, survival and quality of life. The occurrence of PH will be correlated with clinical parameters, mutation status and progression (liquid biopsies) and immune cell infiltration. Since cytokines released by tumour cells and the perivascular accumulation of immune cells presumably contribute to the pathogenesis of LC-PH, the responsible immune cell types and signalling pathways will be analysed. These investigations should form a solid basis for a pilot study on PH therapy in LC-PH patients and, in the long term, contribute to the further personalisation of lung tumour therapy.
